GlassScriptPhysician profile
Barbara A Scherer
NPI 1225041882
$6,830.15
in general payments reported to CMS, 2019-2025
38 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $960 · 2021: $1,381 · 2022: $1,122 · 2023: $1,109 · 2024: $838 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,378 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.67 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,322.39 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $641.48 | 2019-2025 | Synthroid, Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $581.70 | 2019-2024 | Xarelto |
| Merz North America, INC. | $561.23 | 2020-2025 | Xeomin |
| Astellas Pharma US INC | $524.09 | 2019-2025 | Veozah |
| Allergan, INC. | $379.89 | 2019-2022 | |
| Bausch Health US, LLC | $343.44 | 2020-2022 | |
| Gilead Sciences, INC. | $333.66 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $282.11 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.33 | 2019-2025 | Xifaxan |
| Azurity Pharmaceuticals, INC. | $184.82 | 2023-2024 | Edarbi, Edarbi, Adthyza |
| Galderma Laboratories, L.P. | $174.22 | 2019-2025 | |
| Exact Sciences Corporation | $156.34 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $147.52 | 2022-2023 | Mounjaro |
| Amgen INC. | $138.96 | 2024-2025 | Repatha, Otezla, Repatha |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Scherer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.